Kinnate Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Kinnate Biopharma has a total shareholder equity of $159.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $173.6M and $14.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$154.03m |
| Equity | US$159.33m |
| Total liabilities | US$14.28m |
| Total assets | US$173.61m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6KB's short term assets ($158.2M) exceed its short term liabilities ($12.0M).
Long Term Liabilities: 6KB's short term assets ($158.2M) exceed its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: 6KB is debt free.
Reducing Debt: 6KB has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6KB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6KB has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.1% each year